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In CR patients, HDT-ASCT consolidation improved PFS, PFS2 and OS vs R-Alk consolidation, 
and R- maintenance also enhanced PFS vs no maintenance. The survival advantage with HDT-






Background. High-dose therapy with autologous stem-cell transplantation (HDT-ASCT) and 
maintenance treatment with novel agents are the best options for newly diagnosed multiple 
myeloma patients, increasing the rate of complete response (CR) and prolonging progression-
free survival (PFS) and overall survival (OS). Indeed, the achievement of CR is a predictor of 
long-term survival among transplant-eligible patients. However, it is unclear if patients 
reaching CR after induction treatment may receive a less intense consolidation or avoid 
maintenance therapy. 
Patients and Methods. We analysed CR patients treated in 2 phase III trials, GIMEMA-RV-
MM-209 and EMN-441, to compare HDT-ASCT to a lenalidomide-alkylator regimen (R-Alk) as 
consolidation, and R maintenance to no maintenance. Primary endpoints were PFS, PFS2 and 
OS from consolidation and from maintenance (_m). 
Results. Overall, 166 patients in CR were analysed, 95 in the HDT-ASCT groups and 71 in the 
R-Alk group. CR patients who received HDT-ASCT had a prolonged PFS (HR 0.55, p=0.01), 
PFS2 (HR 0.46, p=0.02) and OS (HR 0.42, p=0.03) as compared to patients randomized to R-
Alk. The survival benefit with HDT-ASCT was confirmed among all the subgroups, according 
to age, ISS stage, cytogenetic profile and maintenance therapy. CR patients who received R-
maintenance had a prolonged 4-year PFS_m (54%vs19%, HR 0.43, p=0.02) as compared to 
those who received no maintenance, while no difference was observed in terms of 4-year 
PFS2_m (72%vs58%, HR 0.83, p=0.67) and 4-year OS_m (79%vs72%, HR: 0.82, p=0.73).  
Conclusion. Even in CR patients, outcomes were improved by an intensified approach with 
HDT-ASCT consolidation and a lenalidomide-based maintenance. 
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Multiple myeloma (MM) is a hematologic neoplasm accounting for approximately 1% of all 
cancers and represents the second most common hematologic malignancy.1 
The introduction of high-dose melphalan (HDT) followed by autologous stem-cell transplant 
(ASCT) and novel agents, such as immunomodulators and proteasome inhibitors (PIs), have 
significantly extended the median overall survival (OS), from 2-3 to 7-8 years of MM 
patients.2–10  
With the increasing availability of highly effective novel agents, the role of the ASCT in newly 
diagnosed MM patients has been questioned, and several trials have been designed to 
compare consolidation with HDT-ASCT to a non-transplant-based approach including novel 
agents. In 4 European phase III trials, newly-diagnosed myeloma patients eligible for 
transplantation were randomized to consolidation with either HDT-ASCT or a novel agent-
containing regimen: melphalan-prednisone-lenalidomide (MPR), cyclophosphamide-
lenalidomide-dexamethasone (CRD), bortezomib-melphalan-prednisone (VMP) or 
bortezomib-lenalidomide-dexamethasone (VRD).11–14 In all the trials, patients in the HDT-
ASCT group had a significantly prolonged PFS as compared to those who did not receive 
transplant, and two of them reported also an OS advantage in favour of the HDT-ASCT 
group.11,12,15–17  
Maintenance treatment with lenalidomide has been extensively investigated among newly 
diagnosed, transplant-eligible patients.11,12,15–17 A meta-analysis of 1208 transplant-eligible 
patients enrolled in 3 randomized phase III trials, comparing lenalidomide maintenance vs 
observation/placebo, showed a 25% reduction in the risk of death in favour of lenalidomide 
maintenance.18 
The adoption of HDT-ASCT and novel agents also dramatically increased the likelihood of 
obtaining a complete response (CR).19,20 Among transplant-eligible patients, the achievement 
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of a CR is related to a significantly improvement of PFS and OS.21 In a meta-analysis evaluating 
the correlation between response depth and survival, patients who achieved a CR, both after 
induction and ASCT, had a significantly longer PFS and OS compared to patients who failed to 
achieve a CR.22 
Here we report the results of a pooled analysis conducted among newly-diagnosed, 
transplant-eligible MM patients enrolled in 2 phase III, randomized clinical trials (GIMEMA-
RV-MM-209 and EMN-441), in order to evaluate the role of intensification and maintenance 







Data on newly-diagnosed, MM patients younger than 65 years of age and eligible for ASCT 
enrolled in 2 randomized, multicenter, phase III trials, namely GIMEMA-RV-MM-209 and 
EMN-441, were pooled together and retrospectively analysed.  
Details on treatment and results of the two trials have been previously published.11,12 The 
institutional review board at each participating centre approved the studies in accordance 
with the Declaration of Helsinki. All patients provided written informed consent. Both trials 
were registered at Clinicaltrials.gov (NCT00551928 and NCT01091831). Briefly, all patients 
received a common induction with four cycles of lenalidomide and low-dose dexamethasone 
(Rd). At enrolment, patients were also randomized in a 1:1:1:1 ratio to receive a consolidation 
treatment with either 2 courses of high-dose melphalan followed by ASCT in both studies, or 6 
cycles of chemotherapy with either melphalan-prednisone-lenalidomide (MPR) in the 
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GIMEMA-RV-MM-209, or cyclophosphamide-lenalidomide-dexamethasone (CRD) in the EMN-
441. Afterwards, they could receive maintenance with lenalidomide (R) alone in both studies, 
or no maintenance in the GIMEMA-RV-MM-209, or lenalidomide-prednisone (RP) 
maintenance in the EMN-441.  
Patients who completed induction treatment and with a confirmed eligibility for 
consolidation, provided that they had reached a CR, at any time during first-line treatment, 
were included in this analysis. Patients were then stratified according to type of consolidation 
treatment, HDT-ASCT or lenalidomide-alkylator based chemotherapy (R-Alk), and type of 
maintenance treatment, lenalidomide-based (R-based) versus no maintenance. 
We analysed the impact of consolidation (HDT-ASCT vs. R-Alk) and maintenance treatment 




In the GIMEMA-RV-MM-209 and EMN-441 trials, responses to treatment were assessed 
according to the International Myeloma Working Group criteria and were confirmed at least 
in 2 consecutive assessments.23  
CR was defined as negative serum and urine immunofixation, disappearance of any soft tissue 
plasmacytoma and less than 5% bone marrow monoclonal plasma cells.  
PFS was calculated from the time of eligibility for consolidation until the date of progression 
or relapse, death from any cause, or the date the patient was last known to be in remission. 
PFS2 was calculated from the time of eligibility for consolidation until the date of second 
progression or relapse, death from any cause, or the date the patient was last known to be in 
remission. OS was calculated from the time of eligibility for consolidation until the date of 
death or the date the patient was last known to be alive. To evaluate the impact of 
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maintenance, all survival outcomes were calculated from date of eligibility for maintenance 
phase (PFS_m, PFS2_m, OS_m). Time to CR was calculated from the data of start of treatment 
to the date of first CR detection. Duration of CR was calculated from the time of CR 
achievement until the date of progression, relapse, death from any cause, or the date the 
patient was last known to be in remission. High-risk FISH was defined by the presence of at 
least one of del17p, t(4;14) or t(14;16). 
Statistical analysis 
 
For this retrospective, not pre-planned analysis, data from the GIMEMA-RV-MM-209 and 
EMN-441 studies were pooled together and only patients who achieved a CR were included in 
the analysis. 
Baseline characteristics were compared using Fisher Exact test for discrete variables and 
Kruskal–Wallis test for continuous variables.  
Time-to-event data (time to CR, duration of CR, and survival data) were analyzed using the 
Kaplan–Meier method; treatment groups were compared with the log-rank test. The Cox 
proportional hazards models were used to estimate adjusted hazard ratios (HRs) and the 95% 
confidence intervals (CIs) for the main comparisons, and Grambsch and Therneau test for 
testing the proportional hazard assumption.  
To account for potential confounders, the Cox models for the comparison “HDT-ASCT” vs. “R-
Alk” were adjusted for age, sex, International Staging System (ISS) stage, cytogenetic profile 
and trial effect. Subgroup analyses were performed to determine the consistency of treatment 
effects of  “HDT-ASCT” vs “R-Alk” in the different subgroups using interaction terms between 
treatment and age, sex, ISS stage, cytogenetic profile and maintenance treatment. All HRs 
were estimated with their 95% confidence intervals (95%CI) and two-sided p-values. 








A total of 791 newly diagnose MM patients enrolled in the GIMEMA-RV-MM-209 (402) and in 
the EMN-441 (389) trials were evaluated. Of them, 166 (21%) were eligible for randomization 
to consolidation after completing induction treatment and had achieved a CR during the 
whole first-line treatment, and they were therefore included in the analysis: 93 from 
GIMEMA-RV-MM-209 and 73 from EMN-441. 
Among patients who achieved a CR, 95 (57%) received HDT-ASCT consolidation, while 71 
(43%) R-Alk consolidation.  
Among patients who achieved a CR, 122 (73%) were assigned to R-based maintenance: 40 
(24%) with RP and 82 with R (49%); while 44 (27%) were randomized to no maintenance. 
No significant difference in the distribution of patients in CR randomized to RP, R and no 
maintenance was observed in the HDT-ASCT group (24%, 47% and 28%, respectively) and in 
the R-Alk group (24%, 52% and 24%, respectively) (p=0.80). 
Patients’ characteristics were well balanced within the HDT-ASCT and the R-Alk groups (table 
1). Median age at enrolment was 57 years (IQR 51 –60 years) for the entire population. 
Patients considered at high risk, according to ISS stage (ISS III: 15% vs 21%, p=0.45), R-ISS 
stage (R-ISS III: 3% vs 6%, p=0.60), and FISH (14% vs 14%, p=1), were equally distributed in 
the two groups.  
 




In the HDT-ASCT group, 18 (19%) patients achieved CR during induction, 33 (35%) after 
HDT-ASCT consolidation and 44 (46%) during maintenance; in the R-Alk group, 29(41%) 
patients achieved CR during induction, 17 (24%) after R-Alk consolidation and 25 (35%) 
during maintenance. 
Overall, the median time to CR was 11.9 months (95% CI 10.2 – 14.5); median time to CR was 
13.5 months in the HDT-ASCT group and 9.5 months in the R-Alk group (HR 0.73, 95% CI 0.53 
– 1.01; p=0.06).  
The median duration of CR was 45.3 months in the HDT-ASCT and 30.5 months in the R-Alk 
group (HR 0.60; p=0.03). 
 
Impact of treatment strategy on survival outcomes 
 
After a median follow-up of 48 months (IQR, 45-52 months), median PFS was significantly 
longer in HDT-ASCT patients as compared to R-Alk patients (NR vs 37 months; HR: 0.55, 95% 
CI 0.35 - 0.88; p=0.01); 5-year PFS was 55% in the HDT-ASCT group and 45% in the R-Alk 
group (Figure 1A).  
Five-year PFS2 was significantly longer among patients in the HDT-ASCT group as compared 
to the R-Alk group (5-year PFS2: 71% vs 62%; HR: 0.46, 95% CI 0.24 - 0.87; p=0.02; Fig 1B). 
Patients who received HDT-ASCT consolidation had a 58% reduced risk of death as compared 
to those randomized to R-Alk consolidation (5-year OS: 87% vs 71%HR: 0.42, 95% IC 0.19 - 
0.92; p=0.03) (Figure 1C). 
In a subgroup analysis accounting for age, sex, ISS stage, cytogenetic risk by FISH and type of 
maintenance, the advantage in terms of PFS, PFS2 and OS reported in CR-patients treated with 
HDT-ASCT over R-Alk was confirmed in all subgroups (Figure 2).  
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To account for the different time-points at which patients achieved CR in the HDT-ASCT and 
R-Alk groups, we also conducted a sensitivity analysis in the entire patient population of the 
two trials examined, with CR as a time-dependent variable. The Cox model was also adjusted 
for age, sex, ISS stage, cytogenetic profile and trial effect. This analysis confirmed the 
advantage in terms of PFS (HR: 0.52, 95% IC 0.40 – 0.65; p<0.001), PFS2 (HR: 0.54, 95% IC 
0.40 – 0.72; p<0.001) and OS (HR: 0.51, 95% IC 0.35– 0.75; p<0.001) for patients who 
underwent HDT-ASCT consolidation as compared to those who received R-Alk.  
 
 
Impact of consolidation strategy on survival outcomes 
 
To better describe the impact of consolidation treatment on survival outcomes, we conducted 
an analysis including only patients who had reached a CR after the induction phase and prior 
to consolidation (Figure 2). Forty-seven patients attained a CR after the induction phase, 18 
patients in the HDT-ASCT group and 29 patients in the R-Alk group. Patients in CR after 
induction treatment who received HDT-ASCT consolidation had an improved 4-year PFS 
(52% vs 33%, HR 0.55, 95% CI 0.22 - 1.40; p=0.21), 4-year PFS2 (82% vs 51%, HR: 0.42, 95% 
CI 0.11 - 1.56; p=0.20) and 4-year OS (88% vs 63%; HR: 0.50, 95% CI 0.09 - 2.63; p=0.41) as 
compared to patients who received R-Alk consolidation, though not statistically significant.  
 
Impact of maintenance on survival outcomes 
 
To better define the role of maintenance treatment, we performed an analysis from the time 
of eligibility confirmation for maintenance, including patients who had achieved a CR after 
consolidation therapy with either HDT-ASCT or R-Alk, or during the first 3 months of 
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maintenance phase (Figure 3). Of them, 72 patients received maintenance: 51 with R and 21 
with RP; whereas, 37 did not receive maintenance. Patients in CR after the consolidation 
phase who received maintenance treatment had a statistically significant prolonged 4-year 
PFS_m (54% vs 19%, HR 0.43, 95% CI 0.21 - 0.86; p=0.02) as compared to patients who did 
not receive maintenance, while no differences were observed in terms of both 4-year PFS2_m 
(72% vs 58%, HR: 0.83, 95% CI 0.35 - 1.97; p=0.67) and 4-year OS_m (79% vs 72%; HR: 0.82, 
95% CI 0.26 - 2.56; p=0.73). 
A trend, though not statistically significant, towards better 4-year PFS_m (71% vs 47%; HR 
0.41, 95% CI 0.14 – 1.21; p=0.11), 4-year PFS2_m (86% vs 65%; HR: 0.38, 95% CI 0.09 – 1.57; 
p= 0.18) and 4-year OS_m (86% vs 75%; HR 0.41, 95% CI 0.09 – 1.83; p=0.24) was observed 





ASCT and novel agents have dramatically improved the rate and quality of remissions, 
ultimately resulting in prolonged PFS and OS.2–8  
Several studies in the ASCT setting confirmed the role of CR as a predictor of long-term PFS 
and OS.2,3,21,24 In a meta-analysis of patients who received HDT-ASCT, those who obtained a 
CR post HDT-ASCT had a 38% reduced risk of progression or death and a 41% reduced risk of 
death as compared to patients who failed to achieve a CR. Furthermore, a significant 
correlation between the achievement of CR after induction therapy and long-term PFS and OS 
was found.22 Patients treated in Total-Therapy-Program (TT1, 2 and 3) who achieved a CR 
showed longer event-free survival and OS in comparison with those who did not, with the 
highest benefit in patients with an early onset and sustained CR (longer than 3 years).25,26  
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However, as previously suggested, CRs may not all be of the same quality. Among CR patients 
in the VISTA study, the duration of CR was 24 months with VMP and 12.8 with MP, suggesting 
deeper responses in patients who received bortezomib as compared to those who did not.27   
To assess the value of treatment intensification with different consolidation and maintenance 
strategies in CR patients, we evaluated 166 patients who achieved a CR and were randomized 
to either HDT-ASCT or R-Alk consolidation. Patients in the HDT-ASCT group had statistically 
significant prolonged 5-year PFS (55% vs. 45%), 5-year PFS2 (71% vs. 62%) and 5-year OS 
(87% vs. 71%) as compared to patients in the R-Alk group and this benefit was independent 
of ISS status, cytogenetic risk and maintenance therapy.  
The incorporation of novel agents in the upfront treatment of MM patients has undoubtedly 
questioned the role of HDT-ASCT consolidation, and several trials have been designed to 
compare HDT-ASCT with a non-transplant consolidation. In the GIMEMA-RV-MM-209 and 
EMN-441 trials, patients randomized to HDT-ASCT had a significantly longer PFS (HR: 0.44 
and 0.4, respectively) and OS (HR: 0.55 and 0.42, respectively) than those who received a R-
Alk consolidation.11,12 The phase III HOVON65/EMN02 trial compared HDT-ASCT vs VMP 
consolidation in ASCT-eligible patients, and preliminary results showed that patients who 
underwent HDT-ASCT had a prolonged PFS (HR: 0.76) as compared to those who did not.13 
Even when compared to a combination of lenalidomide-bortezomib-dexamethasone (RVD) 
consolidation, HDT-ASCT significantly prolonged PFS (HR: 0.65).14  
In our analysis, although all the analysed patients had achieved a CR, HDT-ASCT consolidation 
still induced superior survival outcomes as compared to R-Alk consolidation. To better 
describe the role of HDT-ASCT, we narrowed our analysis to the subgroup of patients in CR 
before consolidation: again, patients who received HDT-ASCT had a trend toward a longer 4-
year PFS (52% vs. 33%), PFS2 (82% vs. 51%) and OS (88% vs. 63%) as compared to patients 
randomized to R-Alk consolidation. The lack of statistical significance is likely due to the 
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reduced number of patients included in this subgroup analysis, as well as the low number of 
events observed. 
One possible explanation for this finding could be a better depth of CR, in terms of minimal-
residual disease (MRD), obtained with HDT-ASCT as compared to R-Alk. MRD by multi-
parameter flow-cytometry (MFC, sensitivity of 10-4) analysis was performed in 50 patients in 
the EMN-441 study, 16 of whom had reached a CR. In this sub-study, despite an equal number 
of patients achieving at least a very good partial response (VGPR), patients who received 
HDT-ASCT consolidation were more likely to reach MRD negativity (63%) as compared to 
those who received R-Alk (37%). Likewise, in the IFM2009 trial comparing consolidation with 
either HDT-ASCT vs RVD, patients in the ASCT group were more likely to obtain MRD 
negativity (79% vs. 65%, p>0.001) as compared to patients in the RVD arm,14 while in MRD 
negative (sensitivity of 10-6) patients, no differences in terms of outcomes were noted among 
patients of the ASCT and RVD arms.28 
These data support our hypothesis that the advantage with HDT-ASCT over R-Alk in CR 
patients is likely attributable to a higher MRD negativity rate induced by HDT-ASCT. 
The benefit of HDT-ASCT was seen in all subgroups included in the multivariate analysis, 
regardless of sex, ISS stage, cytogenetic risk by FISH and maintenance treatment.   
Interestingly, the benefit with HDT-ASCT was greater in patients with low-risk disease by ISS 
(ISS I) than in those with high-risk disease (ISS II/III), possibly reflecting that a more sensitive 
disease benefits more from an intensive treatment.  
Lenalidomide has been extensively investigated as maintenance in younger patients after 
HDT-ASCT.11,12,15,16 In a meta-analysis including 3 phase III trials in newly diagnosed patients, 
lenalidomide maintenance after HDT-ASCT significantly reduced the risk of progression or 
death by 52%, and the risk of death by 25% as compared to observation/placebo.16 The PFS 
and OS advantage reported with lenalidomide was confirmed also in VGPR or CR patients 
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before maintenance. Moreover, as shown in the FIRST trial, continuous treatment in CR 
patients significantly prolonged the duration of response as compared to fixed-duration 
treatment (median, 59 vs. 40 months).29  
In this analysis, we confirmed the benefit of continuous treatment with lenalidomide even in 
patients in CR after HDT-ASCT; as a matter of fact, lenalidomide maintenance resulted in a 
68% reduction in the risk of progression or death compared with no maintenance. A longer 
follow-up is needed to detect any difference in terms of PFS2_m and OS_m between the two 
groups.  
Since HDT-ASCT and novel agents have increased the chances of reaching a CR and because 
the achievement of a CR is associated with long-term survival, whether the achievement of CR 
can be considered a reliable-enough endpoint to guide treatment selection is still under 
debate. However, the heterogeneity of outcomes with different MRD negativity rates in CR 
patients, and the benefit displayed by HDT-ASCT and maintenance treatment in this 
population, suggest that treatment intensification in patients with negative serum and urine 
immunofixation should be pursued with the goal of MRD negativity. Indeed, MRD is a stronger 
predictor of long-term outcomes as compared to standard CR, and has therefore been 
incorporated in the updated IMWG response criteria published in 2016.30 Whether the 
achievement of MRD negativity might guide treatment decision, such as intensification with 
HDT-ASCT or maintenance therapy, as for other haematological malignancies, needs to be 
addressed in clinical trials.31,32 
This study has some limitations. First, the lack of a comprehensive MRD dataset of patients 
included in this analysis does not allow us to confirm whether the difference in survival 
outcomes between HDT-ASCT and R-Alk is due to a different burden of residual disease; 
however, data from the MRD analysis conducted among a subset of patients in the EMN-441 
study included in this analysis and from the MRD study of patients in the IFM2009 study seem 
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to support this hypothesis. Another limitation is that patients included in the analysis did not 
receive a proteasome inhibitor (PI) as part of their initial treatment. Indeed, a three-drug 
regimen combining either thalidomide or lenalidomide, and a PI, bortezomib, has already 
proven to be superior to a two-drug regimen including thalidomide or lenalidomide as 
induction treatment before HDT-ASCT. 7,33 In a phase I/II trial, 20 out of 22 patients (91%) in 
CR after upfront treatment with carfilzomib-lenalidomide-dexamethasone were MRD 
negative. Similarly, in the relapse setting, three-drug combinations including daratumumab-
lenalidomide-dexamethasone (DaraRd) or daratumumab-bortezomib-dexamethasone 
(DaraVd), resulted in higher CR and MRD negativity rates as compared to two-drug 
regimens.34,35 
However, as shown by the IFM2009 French study, even in patients treated with RVD, HDT-
ASCT resulted in a higher rate of CR and a doubling of MRD negativity than RVD consolidation, 
supporting the benefit of HDT-ASCT. 
In conclusion, we demonstrated that in patients who achieved a CR, consolidation with HDT-
ASCT prolonged PFS, PFS2 and OS compared with non-transplant approach, and a 
lenalidomide-based maintenance induced a better PFS_m than no maintenance. This is the 
first data-set showing that, among CR patients, the choice of consolidation continues to favour 
the use of HD-ASCT independently of ISS stage and cytogenetic risk. Our analysis indirectly 
confirmed that the goal of MM treatment is to obtain sustained CR and MRD negativity. 
 
Clinical Practice Points 
 
The role of high-dose therapy and autologous stem cell transplantation (HDT-ASCT) in newly 
diagnosed myeloma (MM) patients has been called into question by the introduction of novel 
agents. Nevertheless, ASCT still remains a standard of care in this setting, as well as 
lenalidomide maintenance after ASCT, which has shown to prolong both PFS and OS. To 
address the role of ASCT and maintenance in patients attaining a complete remission (CR), we 
conducted a pooled analysis among newly-diagnosed, transplant-eligible MM patients 
enrolled in 2 phase III, randomized clinical trials (GIMEMA-RV-MM-209 and EMN-441), 
comparing HDT-ASCT to a lenalidomide-alkylator regimen (R-Alk) as consolidation, and R 
maintenance to no maintenance. 
17 
 
Overall, 166 patients in CR were analysed. CR patients who received HDT-ASCT had a 
prolonged PFS (HR 0.55, p=0.01), PFS2 (HR 0.46, p=0.02) and OS (HR 0.42, p=0.03) as 
compared to patients randomized to R-Alk. The survival benefit with HDT-ASCT was 
confirmed among all the subgroups, according to age, ISS stage, cytogenetic profile and 
maintenance therapy. CR patients who received R-maintenance had a prolonged 4-year 
PFS_m (54% vs 19%, HR 0.43, p=0.02) as compared to those who received no maintenance. 
Our results demonstrate that, even in patients attaining a CR, the choice of HDT-ASCT 
consolidation, independently of ISS stage and cytogenetic risk, and of prolonged lenalidomide-




1.  Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-1060. 
doi:10.1056/NEJMra1011442 
2.  Attal M, Harousseau J-L, Stoppa A-M, et al. A Prospective, Randomized Trial of 
Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma. N 
Engl J Med. 1996;335(2):91-97. doi:10.1056/NEJM199607113350204 
3.  Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-
cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875-1883. 
doi:10.1056/NEJMoa022340 
4.  Moreau P, Avet-Loiseau H, Harousseau J-L, Attal M. Current trends in autologous stem-
cell transplantation for myeloma in the era of novel therapies. J Clin Oncol. 
2011;29(14):1898-1906. doi:10.1200/JCO.2010.32.5878 
5.  Benson DM, Panzner K, Hamadani M, et al. Effects of induction with novel agents versus 
conventional chemotherapy on mobilization and autologous stem cell transplant 
outcomes in multiple myeloma. Leuk Lymphoma. 2010;51(2):243-251. 
doi:10.3109/10428190903480728 
6.  Harousseau J-L, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is 
superior to vincristine plus doxorubicin plus dexamethasone as induction treatment 
prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: 
18 
 
results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010;28(30):4621-4629. 
doi:10.1200/JCO.2009.27.9158 
7.  Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus 
dexamethasone compared with thalidomide plus dexamethasone as induction therapy 
before, and consolidation therapy after, double autologous stem-cell transplantation in 
newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 
2010;376(9758):2075-2085. doi:10.1016/S0140-6736(10)61424-9 
8.  Sonneveld P, Schmidt-Wolf IGH, van der Holt B, et al. Bortezomib induction and 
maintenance treatment in patients with newly diagnosed multiple myeloma: results of 
the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol. 2012;30(24):2946-
2955. doi:10.1200/JCO.2011.39.6820 
9.  Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma 
and the impact of novel therapies. Blood. 2008;111(5):2516-2520. doi:10.1182/blood-
2007-10-116129 
10.  Rajkumar SV. Myeloma today: Disease definitions and treatment advances. Am J 
Hematol. 2016;91(1):90-100. doi:10.1002/ajh.24236 
11.  Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy 
in multiple myeloma. N Engl J Med. 2014;371(10):895-905. 
doi:10.1056/NEJMoa1402888 
12.  Gay F, Oliva S, Petrucci MT, et al. Chemotherapy plus lenalidomide versus autologous 
transplantation, followed by lenalidomide plus prednisone versus lenalidomide 
maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 
trial. Lancet Oncol. 2015;16(16):1617-1629. doi:10.1016/S1470-2045(15)00389-7 
13.  Cavo M, Beksac M, Dimopoulos MA, et al. Intensification Therapy with Bortezomib-
Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly 
19 
 
Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the 
European Myeloma Network (EMN02/HO95 MM Trial). Blood. 2016;128(22):Abstract 
#673 [ASH 2016 58th Meeting]. 
http://www.bloodjournal.org/content/128/22/673?sso-checked=true. Accessed 
October 27, 2017. 
14.  Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, Bortezomib, and 
Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017;376(14):1311-
1320. doi:10.1056/NEJMoa1611750 
15.  Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide Maintenance after Stem-Cell 
Transplantation for Multiple Myeloma. N Engl J Med. 2012;366(19):1782-1791. 
doi:10.1056/NEJMoa1114138 
16.  McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell 
transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770-1781. 
doi:10.1056/NEJMoa1114083 
17.  Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide Is a Highly Effective Maintenance 
Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study. 
Blood. 2016;128(22):Abstract #1143. 
http://www.bloodjournal.org/content/128/22/1143?sso-checked=true. 
18.  McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide Maintenance After 
Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-
Analysis. J Clin Oncol. 2017;35(29):3279-3289. doi:10.1200/JCO.2017.72.6679 
19.  Bladé J, Samson D, Reece D, et al. CRITERIA FOR EVALUATING DISEASE RESPONSE AND 
PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH-DOSE 




20.  Durie BGM, Harousseau J-L, Miguel JS, et al. International uniform response criteria for 
multiple myeloma. Leukemia. 2006;20(9):1467-1473. doi:10.1038/sj.leu.2404284 
21.  Lahuerta JJ, Mateos MV, Martínez-López J, et al. Influence of pre- and post-
transplantation responses on outcome of patients with multiple myeloma: sequential 
improvement of response and achievement of complete response are associated with 
longer survival. J Clin Oncol. 2008;26(35):5775-5782. doi:10.1200/JCO.2008.17.9721 
22.  van de Velde H, Londhe A, Ataman O, et al. Association between complete response and 
outcomes in transplant-eligible myeloma patients in the era of novel agents. Eur J 
Haematol. 2017;98(3):269-279. doi:10.1111/ejh.12829 
23.  Kyle RA, Rajkumar S V. Criteria for diagnosis, staging, risk stratification and response 
assessment of multiple myeloma. Leukemia. 2009;23(1):3-9. doi:10.1038/leu.2008.291 
24.  Alvares CL, Davies FE, Horton C, et al. Long-term outcomes of previously untreated 
myeloma patients: responses to induction chemotherapy and high-dose melphalan 
incorporated within a risk stratification model can help to direct the use of novel 
treatments. Br J Haematol. 2005;129(5):607-614. doi:10.1111/j.1365-
2141.2005.05514.x 
25.  Pineda-Roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple 
myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J 
Haematol. 2008;140(6):625-634. doi:10.1111/j.1365-2141.2007.06921.x 
26.  Barlogie B, Anaissie E, Haessler J, et al. Complete remission sustained 3 years from 
treatment initiation is a powerful surrogate for extended survival in multiple myeloma. 
Cancer. 2008;113(2):355-359. doi:10.1002/cncr.23546 
27.  San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone 




28.  Avet-Loiseau H, Lauwers-Cances V, Corre J, Moreau P, Attal M, Munshi N. Minimal 
Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial. Blood. 
2017;130(Suppl 1):Abstract #435 [ASH 2017 59th Meeting]. 
29.  Bahlis NJ, Corso A, Mugge L-O, et al. Benefit of continuous treatment for responders 
with newly diagnosed multiple myeloma in the randomized FIRST trial. Leukemia. 
2017;31(11):2435-2442. doi:10.1038/leu.2017.111 
30.  Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus 
criteria for response and minimal residual disease assessment in multiple myeloma. 
Lancet Oncol. 2016;17(8):e328-e346. doi:10.1016/S1470-2045(16)30206-6 
31.  Rossi D, Ferrero S, Bruscaggin A, et al. A Molecular Model for the Prediction of 
Progression Free Survival in Young Mantle Cell Lymphoma Patients Treated with 
Cytarabine-Based High Dose Sequential Chemotherapy and Autologous Stem Cell 
Transplantation: Results from the MCL0208 Phase III Trial fr…. Blood. 
2015;126(23):Abstract #336 [ASH 2015 57th Meeting]. 
http://www.bloodjournal.org/content/126/23/336. Accessed February 15, 2018. 
32.  Saußele S, Richter J, Hochhaus A, Mahon F-X. The concept of treatment-free remission in 
chronic myeloid leukemia. Leukemia. 2016;30(8):1638-1647. 
doi:10.1038/leu.2016.115 
33.  Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and 
dexamethasone versus lenalidomide and dexamethasone alone in patients with newly 
diagnosed myeloma without intent for immediate autologous stem-cell transplant 
(SWOG S0777): a randomised, open-label, phase 3 trial. Lancet (London, England). 
2017;389(10068):519-527. doi:10.1016/S0140-6736(16)31594-X 
34.  Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, Bortezomib, and 




35.  Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, Lenalidomide, and 





Tables and figures: titles and legends 
 
Table 1. Patient characteristics 
 
Legend. *High-risk cytogenetics by FISH is defined by the presence of at least one of the following: del17p, 
t(4;14) or t(14;16). HDT-ASCT, high-dose therapy with autologous stem-cell transplantation; R-Alk, 
lenalidomide-alkylator; R, lenalidomide; RP, lenalidomide-prednisone; ISS, International Staging System; RISS, 
Revised ISS; IQR, interquartile range. 
 
Figure 1. ASCT vs R-Alk 
1a. PFS 
1b. PFS – MULTIVARIATE ANALYSIS 
1c. PFS2 
1d. PFS2 – MULTIVARIATE ANALYSIS 
1e. OS 
1f. OS – MULTIVARIATE ANALYSIS 
 
Legend. HDT- ASCT, high-dose therapy autologous stem-cell transplantation; R-Alk, lenalidomide-alkylator 
based chemotherapy; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence 
interval; p, p-value; Len, lenalidomide; ISS, International Staging System. 
 
 
Figure 2. HDT-ASCT vs R-Alk: Analysis from time to eligibility confirmation for 
consolidation phase 
2a. PFS 
2b. PFS2  
2c. OS 
 
Legend. HDT- ASCT, high-dose therapy autologous stem-cell transplantation; R-Alk, lenalidomide-alkylator 
based chemotherapy; PFS, progression-free survival; OS, overall survival, HR, hazard ratio; CI, confidence 
interval; p, p-value. 
 
 
Figure 3. Maintenance vs no maintenance – analysis from time to eligibility 





Legend. _m, maintenance; PFS, progression-free survival; OS, overall survival, HR, hazard ratio; CI, confidence 













Age Median (IQR) 56.5 (51-60) 57 (51-61.5) 56 (50.5-60) 
  ≤60 125 (75) 67 (71) 58 (82) 
  >60 41 (25) 28 (29) 13 (18) 
Sex M 79 (48) 46 (48) 33 (46) 
  F 87 (52) 49 (52) 38 (54) 
ISS Stage I 83 (50) 47 (49) 36 (51) 
  II 54 (33) 34 (36) 20 (28) 
  III 29 (17) 14 (15) 15 (21) 
RISS I 44 (27) 25 (26) 19 (27) 
  II 79 (48) 48 (51) 31 (44) 
  III 7 (4) 3 (3) 4 (6) 
  Missing 36 (22) 19 (20) 17 (24) 
Cytogenetic risk* Standard 87 (52) 51 (54) 36 (51) 
  High 23 (14) 13 (14) 10 (14) 
  Missing 56 (34) 31 (33) 25 (35) 
Maintenance None 44 (27) 27 (28) 17 (24) 
  R 82 (49) 45 (47) 37 (52) 
  RP 40 (24) 23 (24) 17 (24) 
Protocol EMN-441 73 (44) 43 (45) 30 (42) 
  GIMEMA-RV-MM-209 93 (56) 52 (55) 41 (58) 
Follow-up Median (IQR) 48 (45-52) 48 (44 -52) 47 (45-50) 
 
*High-risk cytogenetics by FISH is defined by the presence of at least one of the following: del17p, t(4;14) or 
t(14;16). HDT-ASCT, high-dose therapy with autologous stem-cell transplantation; R-Alk, lenalidomide-alkylator; 
R, lenalidomide; RP, lenalidomide-prednisone; ISS, International Staging System; RISS, Revised ISS; IQR, 
interquartile range. 
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